1. Scrip
  2. >>Business

Pfizer Ends Pact With GlycoMimetics After SCD Failure

Rivipansel’s Sickle Cell Disease Trial Failure Triggered Pfizer’s Move

 
• By Sten Stovall

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.  

Contract_Termination
GlycoMimetics To Decide Whether Or Not To Continue Rivipansel Program • Source: Shutterstock

Six months after the failure of a Phase III study evaluating rivipansel for the treatment of vaso-occlusive crisis in sickle cell disease (SCD) patients, Pfizer Inc. has told licensor GlycoMimetics Inc. that it will tear up their 2011 agreement to develop the drug.

GlycoMimetics in a filing with the US Securities and Exchange Commission dated 5 February said Pfizer’s decision meant it would regain all rights to the respective assets and incur no termination penalties related to the end of the partnership. Pfizer licensed the pan-selectin inhibitor from GlycoMimetics in October 2011 in a $340m deal

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.